Loading...
Sign in to edit your profile (add interests, overview, photo, etc.)

    Yazdanian, Mehrangiz

    TitleResearch Assoc Principal
    SchoolLawrence Berkeley National Lab
    DepartmentBldg Technology Urban Systems
    Address1 Cyclotron Road
    Berkeley CA 94720
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Bou-Chacra N, Melo KJC, Morales IAC, Stippler ES, Kesisoglou F, Yazdanian M, Löbenberg R. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. AAPS J. 2017 May 17. PMID: 28516359.
        View in: PubMed
      2. Bergström CA, Yazdanian M. Lipophilicity in Drug Development: Too Much or Not Enough? AAPS J. 2016 Sep; 18(5):1095-100. PMID: 27393481.
        View in: PubMed
      3. Parr A, Hidalgo IJ, Bode C, Brown W, Yazdanian M, Gonzalez MA, Sagawa K, Miller K, Jiang W, Stippler ES. The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers. Pharm Res. 2016 Jan; 33(1):167-76. PMID: 26286187.
        View in: PubMed
      4. Yazdanian M. Overview of determination of biopharmaceutical properties for development candidate selection. Curr Protoc Pharmacol. 2013 Mar; Chapter 9:Unit9.17. PMID: 23456615.
        View in: PubMed
      5. James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Mol Cancer Ther. 2012 Apr; 11(4):930-41. PMID: 22319199.
        View in: PubMed
      6. Wells-Knecht KJ, Ott GR, Cheng M, Wells GJ, Breslin HJ, Gingrich DE, Weinberg L, Mesaros EF, Huang Z, Yazdanian M, Ator MA, Aimone LD, Zeigler K, Dorsey BD. 2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation. Chem Res Toxicol. 2011 Nov 21; 24(11):1994-2003. PMID: 22023349.
        View in: PubMed
      7. Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem. 2011 Jul 14; 54(13):4781-92. PMID: 21634396.
        View in: PubMed
      8. Mitra P, Audus K, Williams G, Yazdanian M, Galinis D. A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: Implications for intestinal pH and effects on drug absorption. J Pharm Sci. 2011 Oct; 100(10):4258-68. PMID: 21538355.
        View in: PubMed
      9. Bummer PM, Yazdanian M. George Zografi: researcher and educator. Pharm Res. 2006 Oct; 23(10):2235-8. PMID: 16957836.
        View in: PubMed
      10. Young AM, Audus KL, Proudfoot J, Yazdanian M. Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability. J Pharm Sci. 2006 Apr; 95(4):717-25. PMID: 16498570.
        View in: PubMed
      11. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res. 2004 Feb; 21(2):293-9. PMID: 15032311.
        View in: PubMed
      12. Fichert T, Yazdanian M, Proudfoot JR. A structure-permeability study of small drug-like molecules. Bioorg Med Chem Lett. 2003 Feb 24; 13(4):719-22. PMID: 12639566.
        View in: PubMed
      13. Hamilton KO, Yazdanian M, Audus KL. Contribution of efflux pump activity to the delivery of pulmonary therapeutics. Curr Drug Metab. 2002 Feb; 3(1):1-12. PMID: 11876574.
        View in: PubMed
      14. Hamilton KO, Yazdanian M, Audus KL. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int J Pharm. 2001 Oct 9; 228(1-2):171-9. PMID: 11576779.
        View in: PubMed
      15. Hamilton KO, Backstrom G, Yazdanian M, Audus KL. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J Pharm Sci. 2001 May; 90(5):647-58. PMID: 11288109.
        View in: PubMed

      A U.S. Department of Energy National Laboratory Managed by the University of California

      This site is running Profiles RNS version v2.10.1-414-g6fb82b0a.